Pharma & Biotech Insights, Interviews & Features
Biotechnology
14 November 2024 14 November 2024
Today's issue
Refine Search
Biotechnology
This week, we discuss a novel AI-driven approach to drug development, and its potential to transform the treatment of cancer and autoimmune diseases. 14 November 2024
Biotechnology
An Expert View from Cumulus Oncology about its innovative business model, which is all about improving the efficiency of drug R&D. 11 November 2024
Generics
Indian drugmaker Aurobindo Pharma has taken on the might of China in terms of Penicillin G pricing, and is doing so by leveraging a fully integrated production process at its new plant. Anticipating the price erosion of Penicillin G, the company has put up an integrated plant from scratch. 10 November 2024
Pharmaceutical
Life science investors can be divided into two groups: those who bought Novo Nordisk stock before GLP-1s hit the big time, and those who wish they had. 10 November 2024
Generics
Indian markets are abuzz with a singular refrain. Donald Trump's Presidency of the United States is set to open new opportunities for India, especially in the pharmaceutical sector. 8 November 2024
Biotechnology
According to UNICEF's State of the World's Children 2023 report, in Latin America
and the Caribbean, 6.8 million children did not benefit from vaccination during the
time of the pandemic and in the following two years, progress has not been as
expected either. 7 November 2024
Biotechnology
As India's bioeconomy soars to a remarkable valuation of $151 billion, the government's Biotechnology Industry Research Assistance Council (BIRAC) has underscored the critical need for innovation and private sector investment to unlock further growth. 21 October 2024
Pharmaceutical
An Expert View from Nick Petschek, Managing Director EMEA, Kotter International. 18 October 2024
Biotechnology
Where once the state of play in the cell and gene therapy space was mostly limited to hope and hype around what might be to come, this is increasingly being replaced by action, on-market therapies and genuine expectation of reaching patients—provided companies can avoid some of the sector’s notorious pitfalls. 16 October 2024
Biotechnology
Antibody-drug conjugates (ADCs) represent a transformative class of cancer therapy that combine the targeting ability of antibodies with the cell-killing potential of cytotoxic drugs. 15 October 2024
Biotechnology
At last month’s European Academy of Dermatology and Venereology (EADV) congress in Amsterdam, Novartis presented new early and long-term Phase III data for remibrutinib in chronic spontaneous urticaria (CSU). 14 October 2024
Biotechnology
India's new Biotechnology Research Innovation and Entrepreneurship Development (Bio-RIDE) scheme is a significant step towards consolidating and advancing the country's biotechnology initiative. 7 October 2024
Pharmaceutical
F2G’s September $100m funding round provides the company with crucial funds to
renavigate approval of its lead drug, olorofim. The substantial financing also
highlights the paucity of novel antifungal products in the clinic. 3 October 2024
Pharmaceutical
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
Pharmaceutical
As stakeholders in the pharmaceutical industry, we all have a responsibility to ensure life-saving treatments promptly and safely reach patients regardless of where they live. To this end, by integrating early access programs and other less conventional strategies into a company’s business model for drug distribution, patients who are suffering from life-threatening conditions can gain access to needed treatments in regions where there is a lack of drug accessibility, while at the same time offering benefits to pharmaceutical companies. 2 October 2024
Pharmaceutical
The Russian government has finalized the rules for granting preference to domestic drugs in public procurements, which will come into force in 2025. 1 October 2024
Pharmaceutical
A Feature on M&A, licensing and partnerships hotting up in inflammatory diseases as new targets present new opportunities for future growth. 30 September 2024
Pharmaceutical
India is set to complete 50 new greenfield pharma manufacturing plants in the next two years under its Production-linked Incentive (PLI) scheme for pharma and medical devices. 30 September 2024
Generics
The number of clinical trials of new drugs in Russia is steadily declining, which could be mainly related with the overall reduction of investment activities in the local pharmaceutical market, reports The Pharma Letter’s local correspondent. 30 September 2024
Pharmaceutical
Scarcely anything unites lawmakers in America these days, but the ostensible iniquities of Big Pharma could be a rare exception. 22 September 2024
Pharmaceutical
A report concludes that the prospect of leaving the European Union (EU) without an agreement that protects the UK’s pharmaceutical industry would be disastrous for just about everyone with a stake in the sector – from drugmakers to patients. 17 May 2018
Pharmaceutical
R-Pharm, one of Russia’s leading drugmakers, has won a tender in Russia for the supply of Viekira Pak (ombitasvir, paritaprevir, ritonarvir tablets, dasabuvir tablets), a drug for the treatment of hepatitis C for state needs this year, according to recent statements of the company and senior officials of the Russian Ministry of Health, reports The Pharma Letter’s local correspondent. 17 May 2018
Biotechnology
AmideBio, a privately held US biotech company, has announced that Dr Pawel Fludzinski has joined the company as its new chief executive. 17 May 2018
Pharmaceutical
Belén Garijo has been the chief executive of the Healthcare business of German life sciences group Merck KGaA since 2015. Speaking to The Pharma Letter, she discusses her company’s quest to overcome the chronic disease ... 17 May 2018
Biotechnology
Sensei Biotherapeutics, a privately-held company known as Panacea Pharmaceuticals until earlier this year, has announced the appointment of John Celebi as chief executive as the company seeks to push forward with its lead cancer vaccine. 16 May 2018
Biotechnology
Cancer immunotherapy firm OncoQuest has appointed industry veteran Dr Eliel Bayever as chief medical officer. 14 May 2018
Biotechnology
As more Chinese pharma companies are seeking potential assets globally, especially biotech startups, they need to be aware of cultural differences, which in some cases could even blow up a deal, noted speaks at ChinaBio partnering forum held in Suzhou on Apr 26, reports The Pharma Letter’s local correspondent Wang Fangqing. 14 May 2018
Biotechnology
Big pharma has spent a lot of money founding or funding small firms recently. This is partly a strategic choice on the part of management - some have a surfeit of candidates, with limited resources and expertise in-house.
But for Dr Kemal Malik, innovation chief and Bayer board member, his firm’s investment in three cell and gene therapy companies looking at early stage science is about more than the economics of R&D. 11 May 2018
Pharmaceutical
The Drugs Controller General of India (DCGI) and the Indian Council of Medical Research (ICMR) have come under fire for approving the human papillomavirus (HPV) vaccine for cervical cancer patients, despite a report by India's Parliament opposing its use. The government, meantime, continues to dither over introducing the HPV vaccine in its Universal Immunization Program, reports The Pharma Letter’s India correspondent. 10 May 2018
Pharmaceutical
UK-based drugmaker GlaxoSmithKline has announced that its chief financial officer Simon Dingemans is to retire. 10 May 2018
Pharmaceutical
Due to the rising cost of drug development in an era when there is pressure to cut costs, pharma companies are losing any incentives to innovate, says Dr Nicola Davies in her monthly exclusive blog for The Pharma Letter. The US Food and Drug Administration Commissioner Scott Gottlieb is keen to address this problem and has sought funding from Congress to incentivize innovation in the pharmaceutical industry.1 So, what exactly are his ideas around spurring innovation within the industry? We discuss six key areas on the Commissioner’s agenda. 10 May 2018
Pharmaceutical
In the latest Expert View piece on artificial intelligence (AI), Christopher Bouton, founder and CEO of Vyasa, a provider of software for the life sciences and healthcare industries, analyzes what the future holds for biopharma in an AI-driven world. 9 May 2018
Biotechnology
Horizon Discovery’s announcement on the identity of its new chief executive on Monday has been followed on Tuesday by a major drop in the share price of the gene editing company. 9 May 2018
Biotechnology
While many western biotech startups are struggling to get funding, their Chinese counterparts seem like a fund magnet, attracting $11.7 billion in venture capital (VC) investment in 2017, more than doubled from 2016, according to the Shanghai-based consulting firm ChinaBio Group, reports The Pharma Letter’s local correspondent Wang Fangqing. 9 May 2018
Pharmaceutical
A new drug for the treatment of lung cancer may soon be launched in the Russian market by Swiss pharma giant Novartis, which registered its Zikadia (ceritinib) in the Russian state register of drugs, aiming to participate in public procurements in Russia later this year, reports The Pharma Letter’s local correspondent. 8 May 2018
Generics
R-Pharm, one of Russia’s leading drugmakers, has won the 1 billion roubles (~$16 million) tender for the supplies of its teriflunomide drug for state needs, according to the company, reports The Pharma Letter’s local correspondent. 8 May 2018
Pharmaceutical
The progress achieved in treating huge swathes of the world’s HIV-infected population in the last 20 to 30 years might give the impression of a therapy area where few challenges remain. 8 May 2018
Pharmaceutical
French independent pharma company Pierre Fabre has named Eric Ducournau as its new chief executive, taking over from Bertrand Parmentier who has announced his retirement. 7 May 2018
Biotechnology
Ahead of the Australian Federal Budget, Chris Nave, chief executive of the Medical Research Commercialization Fund and Managing Director at the venture capital firm Brandon Capital, shares his thoughts on the promising landscape of Australian biotech. 4 May 2018
Pharmaceutical
US pharma major Eli Lilly today announced that Leena Gandhi, a prestigious thoracic oncologist with a focus on immunotherapy and early drug development, will join Lilly Oncology on June 25, 2018 to lead immuno-oncology medical development. 2 May 2018
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze